Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary folate malabsorption (HFM) is an inherited disorder of folate transport characterized by a systemic and central nervous system (CNS) folate deficiency manifesting as megaloblastic anemia, failure to thrive, diarrhea and/or oral mucositis, immunologic dysfunction and neurological disorders.
Features include always present findings: Recurrent infections, Reduced blood folate concentration, Diarrhea, and Folate-responsive megaloblastic anemia. 23 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 7 | Seizure, Ataxia, Irritability |
SLC46A1 function has not been fully characterized.
Hereditary folate malabsorption is associated with mutations in the SLC46A1 gene on chromosome 17.
Hereditary folate malabsorption (HFM) is characterized by folate deficiency with impaired intestinal folate absorption and impaired folate transport into the central nervous system.
HFM should be suspected in infants with the following clinical features, family history, and supportive laboratory and bone marrow examination findings.
Clinical features
No approved treatments are currently available for hereditary folate malabsorption. The disease remains an area of unmet medical need.
No clinical practice guidelines for hereditary folate malabsorption (HFM) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in a child diagnosed with HFM, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Hereditary Folate Malabsorption: Recommended Evaluations Following Initial Diagnosis
The following should be monitored periodically to assess the adequacy of treatment, and more frequently following initial diagnosis when treatment is being optimized. Table 5. Recommended Surveillance for Individuals with Hereditary Folate Malabsorption
No clinical trials have been registered for hereditary folate malabsorption.
4 publications have been identified in PubMed for hereditary folate malabsorption. Kisho has analyzed 3 by research type. Research spans Case Report / Case Series (67%) and Basic Science / Preclinical (33%).
Shekhawat DS (2025). [PMID: 41459184](https://pubmed.ncbi.nlm.nih.gov/41459184/). *EJIFCC*. [Case Report / Case Series]
Nandigrami P (2025). [PMID: 39924111](https://pubmed.ncbi.nlm.nih.gov/39924111/). *The Journal of biological chemistry*. [Basic Science / Preclinical]
N'joumi C (2025). [PMID: 40937236](https://pubmed.ncbi.nlm.nih.gov/40937236/). *Cureus*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 3:29 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
5 |
Recurrent infections, Folate-responsive megaloblastic anemia, Low white blood cell count (decreased total leukocyte count) |
Digestive system | 3 | Malabsorption, Feeding difficulties in infancy, Diarrhea |
Muscles | 2 | Low muscle tone (hypotonia), Generalized hypotonia |
Growth and development | 1 | Failure to thrive |
Hereditary folate malabsorption (HFM) is characterized by (1) impaired intestinal absorption of folates causing systemic folate deficiency and (2) impaired transport of folates across the blood-choroid plexus-cerebrospinal fluid (CSF) barrier, resulting in central nervous system folate deficiency. Infants with HFM may be born with adequate stores of folate but subsequently are unable to absorb folate from breast milk or formula and thus rapidly become folate deficient. Low serum and CSF folate concentrations are documented prior to the onset of clinical signs within one month after birth. One infant presented with pancytopenia (macrocytic) and pneumonia at age one month . Anemia. Folate deficiency results primarily in megaloblastic anemia but often affects all three hematopoietic lineages.
Source: GeneReviews — "Hereditary Folate Malabsorption"
Diarrhea and/or oral mucositis
Infections with unusual organisms (typically pneumonia caused by Pneumocystis jirovecii) associated with hypoimmunoglobulinemia
Neurologic manifestations including developmental delays, cognitive and behavioral disorders, motor disorders, and, frequently, seizures
Source: GeneReviews — "Hereditary Folate Malabsorption"
The differential diagnosis of hereditary folate malabsorption (HFM) includes hereditary disorders , and the following nutritional and pharmacologic conditions: • Vitamin B12 deficiency as a cause of megaloblastic anemia • Nutritional folate deficiency as a result of inadequate dietary folate • Intestinal disease associated with folate malabsorption • The use of phenytoin for the treatment of seizure disorders Table 2. Hereditary Disorders in the Differential Diagnosis of Hereditary Folate Malabsorption
Gene(s) | Disorder | MOI | Key Feature(s) | Comment |
|---|---|---|---|---|
FOLR1 | Cerebral folate transport deficiency1,2 | AR | Very low CSF folate concentrations but, unlike HFM, normal serum folate hemogram. Neurologic signs occur much later, usually in 2nd 3rd yrs of life, although there are earlier exceptions.1 | The defect is due to loss of function of FOLR1, which, along w/PCFT, is required for folate transport into the CSF. |
FTCD | Glutamate formiminotransferase deficiency (OMIM 229100)3 | AR | A severe form of the disorder is assoc w/megaloblastic anemia, DD, cognitive deficits. | FTCD encodes a bifunctional enzyme that channels 1-carbon units from formiminoglutamate (a metabolite of the histidine degradation pathway) to the folate pool. |
MTR (cblG)MTRR (cblE) | Homocystinuria-megaloblastic anemia4 (See Disorders of Intracellular Cobalamin Metabolism.) | AR | Megaloblastic anemia, DD, cognitive other neurologic deficits | MTR MTRR encode 2 enzymes required for methionine synthesis from homocysteine. Age of appearance of disorder ranges from infancy to adulthood depending on specific pathogenic variant. Serum folate is normal. Affected persons respond to cobalamin. |
MTHFD1 | Methylenetetrahydrofolate dehydrogenase 1 deficiency (combined immunodeficiency megaloblastic anemia ± hyperhomocysteinemia) (OMIM 617780) | AR | Early onset, megaloblastic anemia, hemolytic uremic syndrome, microangiopathy w/retinopathy SCID-like syndrome | MTHFD1 is a component of a trifunctional enzyme required for provision of one-carbons in biosynthetic processes. ADA AK2 CD247 CD3D CD3E CORO1A DCLRE1C IL2RG IL7R JAK3 PRKDC PTPRC RAG1 |
RAG2 | Typical SCID (genetically clinically heterogeneous group of disorders w/defective cellular humoral immune function) (See X-Linked SCID.) | XL5AR | Presents in infancy w/recurrent, persistent infections profound lymphopenia w/diminished or absent immunoglobulins | Affected persons have frequent infections w/opportunistic organisms (e.g., Pneumocystis jirovecii, CMV). There may be secondary anemia vitamin deficiencies that may confuse this disorder w/HFM. |
Source: GeneReviews — "Hereditary Folate Malabsorption"
Genetic testing for SLC46A1 is available. Testing is considered confirmatory for diagnosis.
System/Concern | Evaluation | Comment |
|---|---|---|
Hematologic | CBC w/peripheral smear | — |
Immune system | Serum immunoglobulin levels | Neurologic |
counseling | By genetics professionals2 | To inform affected persons their families re nature, MOI, implications of HFM to facilitate medical personal decision making Family support resources |
Source: GeneReviews — "Hereditary Folate Malabsorption"
If possible, folic acid should be avoided as a treatment for HFM. Although folic acid is very stable and inexpensive, and is the most common pharmacologic source of folate, it is not a physiologic folate. Folic acid binds very tightly to folate receptors, which transport the physiologic folate, 5-methylTHF, into cells by an endocytic mechanism . Thus, folic acid may interfere with the interaction between 5-methylTHF and folate receptors required for 5-methylTHF transport across the choroid plexus into the CSF . As indicated above, when the administration of the active (6S) isomer of 5-formylTHF is feasible, it is the preferred form of folate, because unlike the racemic form the entire, versus half, of the dose is effective. Also, the inactive isomer may interfere/compete with transport of the active isomer into cells and its subsequent polyglutamation.
Source: GeneReviews — "Hereditary Folate Malabsorption"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Hereditary Folate Malabsorption"
View trials for hereditary folate malabsorption
Evaluation |
|---|
Frequency |
|---|
Hematologic | CBC | Once remission is achieved: monitor CBC every 6 mos.; Once reliable compliance is established: monitor CBC annually. |
Immunologic | Serum immunoglobulin concentrations | Once immunoglobulin levels are corrected, no need to monitor unless there is compliance issue or suggestive infection. |
Neurologic | Neurologic developmental assessment incl cognitive function | Close follow up w/neurologist most frequently during infancy, then childhood, into adolescence; Changes in neurologic status may warrant re-evaluating CSF folate level. |
Source: GeneReviews — "Hereditary Folate Malabsorption"
Phenotype severity distribution: 4 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).